Newbury Pharmaceuticals Secures Generic Approval for Ivermectin Newbury
Prenumeration
Du har en aktiv prenumeration.
Prenumerera på pressmeddelanden från Newbury Pharmaceuticals via email.
Du prenumererar på följande språk.
Välj vilka språk du vill prenumerera på.
Modular Finance AB kommer att hantera vissa av dina personuppgifter om du väljer att prenumerera. Mer information om vår personuppgiftshantering finns här.
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
2025-10-23 14:30:00
Newbury Pharmaceuticals is pleased to announce the successful Marketing Authorization (MA) of Ivermectin Newbury 10 mg/g cream in Denmark as the first country in a Scandinavian registration procedure. Approvals in Norway and Sweden are expected to follow upon finalized national reviews.
Ivermectin cream is a medication that reduces facial redness caused by rosacea.
Ivermectin Newbury is a generic version of Soolantra. The current annual value of the Scandinavian market is estimated to be 2,8 MEUR according to DLMI Nordic Pharma Insights.
“The successful approval of Ivermectin Newbury highlights Newbury's capability to offer a diverse and comprehensive portfolio and it is Newbury’s first product in dermatology. Based on this positive progress, we plan to launch the product in relevant markets as soon as regulatory exclusivities and patents allow us.” says Mr Lars Minor CEO of Newbury.